Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Integral Diagnostics Ltd. ( (AU:IDX) ) is now available.
Integral Diagnostics Ltd. announced the issuance of 677 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX, indicating a strategic move to incentivize employees and align their interests with company performance.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. operates in the healthcare industry, providing diagnostic imaging services. The company focuses on delivering high-quality radiology services across Australia and New Zealand, catering to a wide range of medical needs.
Average Trading Volume: 1,063,185
Technical Sentiment Signal: Buy
Current Market Cap: A$1.01B
For a thorough assessment of IDX stock, go to TipRanks’ Stock Analysis page.